Natixis Advisors LLC Sells 22,159 Shares of Humana Inc. (NYSE:HUM)

Key Points

• Natixis Advisors LLC reduced its stake in Humana Inc. by 16.9%, now holding 109,259 shares valued at approximately $28.91 million.
• Humana's quarterly earnings showed an EPS of $6.27, missing analysts' expectations, while revenue increased by 9.6% year-over-year to $32.39 billion.
• Currently, Humana has a market capitalization of $29.73 billion and a consensus rating of "Hold" from analysts, with a target price averaging $281.62.

Natixis Advisors LLC cut its stake in Humana Inc. (NYSE:HUM - Free Report) by 16.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,259 shares of the insurance provider's stock after selling 22,159 shares during the period. Natixis Advisors LLC owned 0.09% of Humana worth $28,910,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HUM. Applied Finance Capital Management LLC increased its stake in Humana by 1.7% in the first quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider's stock valued at $779,000 after purchasing an additional 48 shares in the last quarter. Achmea Investment Management B.V. increased its stake in Humana by 0.5% in the first quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider's stock valued at $2,746,000 after purchasing an additional 49 shares in the last quarter. Beech Hill Advisors Inc. boosted its holdings in shares of Humana by 6.1% in the first quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider's stock valued at $229,000 after buying an additional 50 shares during the period. Deseret Mutual Benefit Administrators boosted its holdings in shares of Humana by 15.8% in the first quarter. Deseret Mutual Benefit Administrators now owns 462 shares of the insurance provider's stock valued at $122,000 after buying an additional 63 shares during the period. Finally, Vise Technologies Inc. boosted its holdings in shares of Humana by 8.0% in the fourth quarter. Vise Technologies Inc. now owns 873 shares of the insurance provider's stock valued at $221,000 after buying an additional 65 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Humana stock traded down $0.19 during trading hours on Monday, reaching $247.07. 1,316,283 shares of the stock were exchanged, compared to its average volume of 1,942,637. The company has a market cap of $29.72 billion, a P/E ratio of 18.96, a price-to-earnings-growth ratio of 1.45 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $382.72. The stock has a 50 day moving average of $235.09 and a two-hundred day moving average of $254.92.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. Humana's revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.96 EPS. Equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on HUM shares. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a report on Saturday. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Morgan Stanley reduced their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday. Robert W. Baird dropped their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and an average target price of $281.62.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.